Back HCV Treatment

Adding Ribavirin to Harvoni for Hepatitis C Increases Side Effects But Not Efficacy

Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone, according to an analysis of the Phase 3 ION trials described in the July edition of Hepatology.


Read more: